Sheila Gujrathi - 26 Jun 2024 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Director
Signature
/s/ Maria Dobek, Attorney-in-Fact
Issuer symbol
JANX
Transactions as of
26 Jun 2024
Net transactions value
$0
Form type
4
Filing time
28 Jun 2024, 16:30:43 UTC
Previous filing
07 Jun 2024
Next filing
07 Nov 2024
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Sheila Gujrathi filed Form 4 for Janux Therapeutics, Inc. (JANX) on 28 Jun 2024."

Quick Takeaways

  • This page summarizes Sheila Gujrathi's Form 4 filing for Janux Therapeutics, Inc. (JANX).
  • 2 reported transactions and 1 derivative row are listed below.
  • Filing timestamp: 28 Jun 2024, 16:30.

What Changed

  • Previous filing in this sequence was filed on 07 Jun 2024.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Award $0 +2,500 +2.3% $0.000000 110,528 26 Jun 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (right to buy) Award $0 +8,350 $0.000000 8,350 26 Jun 2024 Common Stock 8,350 $39.80 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.
F2 The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

Sponsored